ADVR Announces Research Collaboration with Northeastern University
News Mar 06, 2008
ADVR scientists will be working with the Department of Chemistry and Chemical Biology to identify how compounds such as AVR118, a Phase II clinical candidate, interact with clinically relevant molecular targets associated with cancer.
In addition to providing greater clarity into how AVR118 exerts its cytoprotective effects, this work is expected to provide valuable insights for producing new generations of product with greater potency and ease of administration.
Another important goal of this agreement is to apply ADVR's innovative AFP Technology to identify new compounds with anti-cancer activity.
In combination with Northeastern's MS and NMR analytical capabilities, the AFP Technology is expected to improve the efficiency of discovering new lead compounds.
“We are excited to be working with this prestigious research institution. Northeastern’s academic environment provides an ideal setting for advancing our understanding of AVR118’s clinical activity and furthering our oncology discovery efforts,” said Vincent P. Gullo, Ph.D., Chief Scientific Officer of ADVR.
Advanced Viral Research Corp. is a New York based biopharmaceutical company dedicated to the discovery and development of small molecule anti-cancer drugs. Its lead compound, AVR118, represents a new class of cytoprotective agent that targets, among other things, some of the most problematic symptoms associated with clinical cachexia or the so called wasting syndrome. In addition, AVR118 has also been shown to possess topical wound healing properties in animal models.
Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Comet "Chury's" Late BirthNews
Comets which consist of two parts, like Chury, can form after a catastrophic collision of larger bodies. Such collisions may have taken place in a later phase of our solar system, which suggests that Chury can be much younger than previously assumed. This is shown through computer simulations.READ MORE
Nanotechnology Detects Molecular Biomarker for OsteoarthritisNews
For the first time, scientists have been able to measure a specific molecule indicative of osteoarthritis and a number of other inflammatory diseases using a newly developed technology. This preclinical study used a solid-state nanopore sensor as a tool for the analysis of hyaluronic acid.READ MORE